Sight Sciences, Inc. (SGHT) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Sight Sciences, Inc. is an ophthalmic medical device company with two reportable segments: Surgical Glaucoma (OMNI and SION systems) and Dry Eye (TearCare system). The company is classified as an emerging growth company and a smaller reporting company. As of June 30, 2024, the company had 50,136,131 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) |
|---|---|---|
| Revenue | $21.37 million | $40.64 million |
| Gross Profit | $18.35 million | $34.82 million |
| Gross Margin | 85.8% | 85.7% |
| Net Loss | $(12.33) million | $(28.60) million |
| Diluted EPS | $(0.25) | $(0.58) |
| Cash and Equivalents | $118.18 million (as of June 30, 2024) | N/A |
| Long-Term Debt | $33.77 million (net) | N/A |
| Operating Cash Flow | N/A | $(19.25) million used |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 9.0% in Q2 2024 compared to Q2 2023.
- Surgical Glaucoma: Revenue fell 5.4% to $20.24 million, driven by lower unit utilization per facility and product mix.
- Dry Eye: Revenue dropped significantly by 45.7% to $1.13 million due to fewer new customers and a strategic shift toward market access initiatives.
- Expense Reduction: Total operating expenses decreased 12.1% to $31.0 million.
- SG&A: Decreased 11.2% primarily due to lower personnel expenses (commissions) and reduced marketing/travel costs.
- R&D: Decreased 17.3% due to reduced clinical study and payroll expenses.
- Debt Refinancing: In January 2024, the company refinanced its MidCap Term Loan with a new $35.0 million facility from Hercules Capital. This resulted in a $2.0 million loss on debt extinguishment recorded in the first half of 2024.
- Legal Proceedings: In April 2024, the company secured a jury verdict of $34 million in damages against Ivantis and Alcon for patent infringement regarding the Hydrus Microstent. The final judgment is subject to appeal and post-trial briefings.
Outlook, Risks, and Management Commentary
- Reimbursement Risks:
- Medicare (Glaucoma): Five Medicare Administrative Contractors (MACs) issued proposed Local Coverage Determinations (LCDs) in May 2024. While they do not characterize OMNI as investigational, they propose non-coverage for multiple MIGS procedures in the same eye, which could reduce volumes. Conversely, CMS proposed "device-intensive" status for OMNI procedures in ASCs for 2025, potentially increasing reimbursement by ~$600 per procedure.
- Dry Eye: No meaningful Medicare or private payer coverage currently exists for TearCare. Management expects a negative impact on cash-pay volumes in H2 2024 due to a price increase effective October 1, 2024. Positive coverage determinations are anticipated in 2025.
- Liquidity: The company holds $118.2 million in cash and has access to additional tranches under the Hercules Loan Agreement (up to $65.0 million total). Management believes this is sufficient to fund operations for at least the next 12 months.
- Strategic Focus: The company is prioritizing disciplined expenditures and cost efficiencies while investing in clinical studies and market access to drive long-term growth.
Investor Verification Checklist
- Medicare Policy Finalization: Monitor the finalization of the proposed MAC LCDs and the CMS 2025 OPPS rule to assess the net impact on Surgical Glaucoma reimbursement and volume.
- Dry Eye Pricing Impact: Verify the actual impact of the October 1, 2024 price increase on TearCare procedure volumes and revenue in Q3 and Q4 2024.
- Legal Settlement: Track the status of the $34 million patent infringement verdict against Ivantis/Alcon, including potential appeals and the timeline for any potential cash recovery.
- Debt Covenants: Confirm continued compliance with the minimum cash and revenue covenants under the new Hercules Loan Agreement.
- Operating Leverage: Assess whether the reduction in SG&A and R&D expenses is sustainable while maintaining the necessary investment for market expansion.